Disclaimer

Forward-Looking Statements

Some of the statements on this website are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements made on this website include, without limitation, our ability to obtain additional funding to continue our clinical trials, fund operations and develop our product candidates; our ability to satisfy any requirements imposed by the FDA (or its foreign equivalents) as a condition of our clinical trials proceeding or beginning as planned; the success or the lack of thereof, including the ability to recruit patients, of our clinical trials through all phases of clinical development; the need to obtain and retain regulatory approval of our drug candidates, both in the United States and in Poland, and in countries deemed necessary for future trials; our ability to complete our clinical trials in a timely fashion and within our expected budget and resources; our compliance with obligations under intellectual property licenses with third parties; the potential efficacy of our drug candidates; our ability to commercialize our drug candidates; our ability to establish or maintain collaborations, licensing or other arrangements; the ability of our sublicense partners to successfully develop our product candidates in accordance with our sublicense agreements; our ability and third parties’ abilities to protect intellectual property rights; and our ability to attract and retain key personnel to manage our business effectively.  These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.  Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.